上皮细胞膜蛋白2在肿瘤侵袭转移中的研究进展  

Research progress of epithelial membrane protein 2 in tumor invasion and metastasis

作　　者：张羽[1] ZHANG Yu(Sichuan Clinical Research Center for Radiation and Therapy/Department of Oncology,Mianyang Central Hospital,Mianyang,Sichuan 621000,P.R.China)

机构地区：[1]四川省放射与治疗临床医学研究中心/绵阳市中心医院肿瘤科,四川绵阳621000

出　　处：《华西医学》2023年第12期1940-1943,共4页West China Medical Journal

基　　金：四川省科学技术厅自然科学基金(2023NSFSC0710)。

摘　　要：上皮细胞膜蛋白(epithelial membrane protein,EMP)2是EMP基因家族的7个蛋白之一,是一种组织特异性表达的跨膜蛋白。近期研究表明,它在不同肿瘤组织中表现出不同的表达模式,并对不同肿瘤的侵袭转移显示出促进或抑制等差异化表现。根据这些特性,目前在抗EMP2治疗领域如单克隆抗体开发等方面取得了进展,可能给癌症治疗带来新手段。基于此,该文对EMP2在肿瘤侵袭转移中的研究进展进行综述,以期为确定肿瘤新标靶提供思路。Epithelial membrane protein(EMP)2 is one of the seven proteins in the EMP gene family and is a tissue-specific transmembrane protein.Recent studies have shown that it exhibits different expression patterns in different tumor tissues and exhibits differentiated manifestations in the invasion and metastasis of different tumors,such as promoting or inhibiting them.Based on these characteristics,progress has been made in the field of anti EMP2 therapy,such as the development of monoclonal antibodies,which may bring new avenues for cancer treatment.Based on this,this article reviews the research progress of EMP2 in tumor invasion and metastasis,in order to provide ideas for determining new tumor targets.

关 键 词：上皮细胞膜蛋白2 肿瘤转移 标靶 

分 类 号：R730[医药卫生—肿瘤]